Takeda Pharmaceutical (TAK) Change in Account Payables (2018 - 2026)

Takeda Pharmaceutical's Change in Account Payables history runs 9 years deep, the most recent figure standing at $30.6 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 54.81% year-over-year to $30.6 million in Q1 2026; TTM through Mar 2026 was -$27.8 million, a 32.72% increase from a year earlier, with the FY2026 full-year figure at -$20.9 million, up 55.22% from the prior year.
• Change in Account Payables improved to $30.6 million in Q1 2026 per TAK's latest filing, from $21.4 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $1.1 billion in Q1 2022 and bottomed at -$751.0 million in Q2 2022.
• The 5-year median for Change in Account Payables is $2.5 million (2024), against an average of $17.3 million.
• Across the five-year window, Change in Account Payables tumbled 302.34% in 2022 and soared 4352.61% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at -$54.6 million in 2022, then jumped by 970.94% to $475.4 million in 2023, then sank by 72.84% to $129.1 million in 2024, then sank by 83.43% to $21.4 million in 2025, then jumped by 43.01% to $30.6 million in 2026.
• Per Business Quant, the three latest TAK Change in Account Payables figures stand at $30.6 million (Q1 2026), $21.4 million (Q4 2025), and $112.2 million (Q3 2025).